October 21, 2021 -- Selecta Biosciences and Genovis have inked a strategic licensing agreement to advance a next-generation immunoglobulin G (IgG) protease for use in gene therapy and certain autoimmune diseases.
The partnership leverages Genovis' proprietary IgG protease, IdeXork (Xork), and Selecta's ImmTOR platform to enable the dosing of transformative gene therapies in patients with preexisting adeno-associated virus immunity and to treat certain IgG-mediated autoimmune diseases.
Under the agreement, Selecta obtains exclusive worldwide rights to Xork.